By the numbers: BoomRay will receive an undisclosed upfront payment and is eligible for development, regulatory and sales milestones, bringing the potential total to $900 million. The company could also receive royalties on future global sales.
Few other details were disclosed, including the asset’s target, isotope or indication. BoomRay described the program only as a preclinical radioligand therapy.
The big picture: Radioligand therapies have become a major part of Novartis’ oncology strategy. The Swiss group entered the field through its $3.9 billion acquisition of Advanced Accelerator Applications in 2018, bringing in Lutathera, before paying $2.1 billion for Endocyte later that year and gaining the program that eventually became prostate cancer drug Pluvicto.
Novartis has continued investing in the technology. In 2024, it agreed to buy Mariana Oncology for $1 billion upfront plus up to $750 million in milestones, adding a preclinical radioligand pipeline and research infrastructure. It is also developing next-generation approaches, including actinium-225-based therapies.
Why it matters: The BoomRay deal comes just one day after another major radiopharma transaction: Australia’s Telix Pharmaceuticals agreed to acquire Munich-based ITM for an initial $1.65 billion (€1.44 billion) paid mostly in Telix’s shares. That deal combines Telix’s commercial radiopharma business with ITM’s isotope manufacturing network and late-stage therapeutic pipeline.